| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 88.6 | 84.1 | 65.9 |
| Other income | 0.4 | -0.2 | 0.7 |
| Total income | 89.1 | 83.8 | 66.6 |
| Profit before exceptional items & tax | 1.1 | 3.2 | 0.2 |
| Profit before tax | 1.1 | 3.2 | 0.2 |
| Net profit | 1.1 | 3.6 | 0.2 |
| Operating margin | 1.2% | 3.8% | 0.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +450.00% |
|---|---|
| Net profit, quarter on quarter | -69.40% |
| Revenue, year on year | +34.40% |
| Operating profit, year on year | +240.00% |
| Operating profit, quarter on quarter | -79.40% |
BSE results filing, NSE: BALPHARMA. Figures extracted from the filing.
Bal Pharma Ltd: key numbers
- Share price
- ₹107.71
- Market cap
- ₹171.5 Cr
- Revenue (annual)
- ₹311.7 Cr
- Net profit (annual)
- ₹6.28 Cr
- P/E (TTM)
- 23.8×Sector 50.4×
- Promoter holding
- 50.86%+0.00% QoQ
- FII holding
- 0.15%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bal Pharma Ltd
All →Bal Pharma Management Change
Bal Pharma Limited announced a change in designations for directors Ravindra Kumar Kothari and Virupakshaya Himesh, effective October 1, 2026.
Bal Pharma Annual General Meeting
Bal Pharma Ltd held its 39th Annual General Meeting on September 24, 2026, where shareholders transacted all business items as per the notice.
Bal Pharma Price Movement Clarification
Bal Pharma has clarified that the recent significant movement in its share price is purely market-driven and not due to any undisclosed price-sensitive information.
Bal Pharma Other Announcement
Bal Pharma Ltd has filed its quarterly shareholding pattern for the period ended March 31, 2026, in compliance with SEBI regulations.
Bal Pharma Capital Structure Change
Bal Pharma Ltd allotted 10,00,000 convertible warrants to its promoter, Mr. Shailesh Siroya, at ₹84 per warrant. This preferential issue aggregates to ₹8.4 Crore.
- Value
- ₹8.40 Cr
Bal Pharma Q4 FY26 Results: Net Profit ₹3.6 Cr, Down 33.3% YoY
Bal Pharma Ltd reported revenue from operations of ₹84.1 Cr (+2.7% YoY) and net profit of ₹3.6 Cr (-33.3% YoY) for Q4 FY26.
- Key figure
- Net profit ₹3.6 Cr · -33.3% YoY